ReviewJournal of midwifery & women's health
Provider-Led Interventions to Reduce Congenital Cytomegalovirus.
Review in Journal of midwifery & women's health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCytomegalovirus (CMV) infection immediately before or during pregnancy can infect a fetus transplacentally, causing congenital CMV (cCMV). cCMV can cause miscarriage, stillbirth, growth restriction, neurodevelopmental delay, hearing, and vision impairment. This integrative review examined original research to better inform health care providers on methods for reducing cCMV infections.
methodsDatabase searching to identify original research pertaining to cCMV prevention in CINAHL, PubMed, and Nursing and Allied Health in January 2024 produced an initial 417 initial studies. Final extraction included 34 studies that met inclusion criteria for analysis.
resultsThree relevant themes emerged: education, screening, and treatment. Messaging and education focused on risk reduction as most effective for behavioral changes. Maternal screening did not predict cCMV in low-risk women; however, it did diagnose early-stage maternal infections. Initiation of treatment closer to infection diagnosis demonstrated better outcomes. The 2 main treatment options for maternal infection were valacyclovir 8 g daily orally and CMV-hyperimmunoglobulin (HIG) 100 or 200 units per kilogram via intravenous (IV) infusion at varying frequency. Research on the efficacy of valacyclovir showed reductions in the incidence of cCMV without adverse maternal effects. Reduction in neonatal transmission and adverse sequelae were more likely with the 200 units per kilogram dosing of IV administration of HIG-CMV compared with the lower dose of 100 units per kilogram. DISCUSSION: cCMV is often overlooked and untreated. Education in a variety of formats is effective at increasing provider knowledge and reducing infection rates by influencing maternal behavior. Screening recommendations are inconsistent but can be used as a tool to identify those pregnant individuals at highest risk, which could facilitate early diagnosis and prompt treatment. Maternal administration of medications such as valacyclovir and HIG-CMV have been shown to reduce the incidence of cCMV. Treatment options for CMV infection in pregnancy and resources for patient education are available and can reduce transmission to the neonate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.